Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Score 3
2024 pubmed

Two livebirths achieved in cases of hypergonadotropic hypogonadism nonobstructive azoospermia, treated with GnRH agonist and gonadotrophins: a case series and review of the literature.

Rose. Mauro Bibancos de MB; Sicard. Arhon Bizelli AB; Aguiar. Natalia Alvarenga NA; Onório. Beatriz de Oliveira BO; Almendra. Antonio Alberto Rodrigues AAR; Matheus. Wagner Eduardo WE; Garolla. Andrea A; Foresta. Carlo C; Braga. Daniela Paes de Almeida Ferreira DPAF; Setti. Amanda Souza AS; Borges. Edson E

Key Findings

  • GnRH agonist (triptorelin) plus menotropin induced sperm production in two men with hypergonadotropic hypogonadism NOA
  • FSH and LH levels fell while testosterone rose after treatment
  • Both couples achieved live births after IVF with ICSI and preimplantation genetic testing

Practical Outcomes

  • The protocol suggests a non‑surgical way to restore sperm in certain infertile men, but it requires careful hormone dosing, monitoring, and access to IVF services. Enthusiasts should view it as experimental and only consider it under professional medical guidance.

Summary

A small study showed that men with a specific type of infertility (high FSH, no sperm) can sometimes start making sperm again when they take a GnRH agonist (triptorelin) to calm the pituitary, followed by hormone shots (menotropin) to stimulate the testes. In both cases, sperm showed up, hormone levels improved, and after IVF with their partners, the couples had healthy babies. The approach could be an alternative to surgical sperm retrieval, but it’s based on only two patients and needs medical oversight.

Abstract

Non-obstructive azoospermia (NOA) is the most severe form of male factor infertility. It results form from either primary or secondary testicular failure. Here, we report cases of two patients with NOA due to maturation arrest and increased serum FSH, treated with GnRH agonist and gonadotrophins. The two NOA patients underwent a pharmacological treatment consisting of pituitary desensibilization using a GnRH agonist and testicular stimulation using menotropin. Testicular stimulation started one month after the beginning of GnRH agonist treatment. The female partner underwent controlled ovarian stimulation (COS) followed by intracytoplasmic sperm injection (ICSI). On the third day of the cycle, menotropin daily doses was administered. When at least one follicle ≥14 mm was visualized, pituitary blockage was performed using GnRH antagonist ganirelix. When three or more follicles attained a mean diameter of ≥17 mm, triptorelin acetate was administered to trigger final follicular maturation. Oocyte retrieval was performed 35 hours later. After treatment, male partner blood levels of the FSH, LH, decreased and total testosterone were increased. Spermatozoa was observed after semen collection in both cases. After COS, oocytes were retrieved and ICSI was performed. Embryos were biopsied for preimplantation genetic testing (PGT) and those considered euploidy were transferred resulting in positive implantation, ongoing pregnancy, and livebirth on both cases. In this report we present a successful strategy for hypergonadotropic hypogonadism AOA men, as an alternative approach to the surgical testicular sperm recovery. Nevertheless, prospective randomized trials are needed to confirm our findings.

Study Information

Provider

pubmed

Year

2024

Date

2024-08-26T00:00:00.000Z

DOI

10.5935/1518-0557.20240039

References

27